Glenmark’s arm gets USFDA’s final approval for Telmisartan, Hydrochlorothiazide Tablets

05 Mar 2019 Evaluate

Glenmark Pharmaceuticals’ subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Telmisartan and Hydrochlorothiazide Tablets USP, 40 mg/12.5 mg, 80 mg/12.5 mg, and 80 mg/25 mg, a generic version of Micardis HCT Tablets, of Boehringer Ingelheim Pharmaceuticals, Inc.

According to IQVIA sales data for the 12 month period ending January 2019, the Micardis HCT Tablets market achieved annual sales of approximately $40.6 million.

The company’s current portfolio consists of 150 products authorized for distribution in the US marketplace and 52 ANDA’s pending approval with the USFDA. The company continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharma Share Price

1965.75 -8.40 (-0.43%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×